Median days of follow-up, number of events, crude incidence rate per 100 person years and hazard ratio of effectiveness and safety outcomes in new users of dabigatran, rivaroxaban or apixaban compared to warfarin for non-valvular atrial fibrillation.

抗凝药物疗效与安全性比较

Median days of follow-up, number of events, crude incidence rate per 100 person years and hazard ratio of effectiveness and safety outcomes in new users of dabigatran, rivaroxaban or apixaban compared

NIAID Data Ecosystem40

Baseline characteristics of non-valvular atrial fibrillation (NVAF) patients taking NOAC, warfarin, and no-treatment after propensity score weighting.

非瓣膜性房颤抗凝治疗

患者基线特征

Baseline characteristics of non-valvular atrial fibrillation (NVAF) patients taking NOAC, warfarin, and no-treatment after propensity score weighting.

NIAID Data Ecosystem20

Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain

非瓣膜性房颤抗凝治疗

抗凝控制预测

Objective: To assess the major clinical factors affecting the quality of anticoagulation and evaluate the predictive value of the SAMe-TT2R2 score to identify patients who will achieve a high average

Figshare2016-08-02 更新10